Saturday, 28 Jun 2025
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA
logo logo
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
  • 🔥
  • Trump
  • House
  • VIDEO
  • White
  • ScienceAlert
  • Watch
  • Trumps
  • man
  • Health
  • Day
Font ResizerAa
American FocusAmerican Focus
Search
  • World
  • Politics
  • Crime
  • Economy
  • Tech & Science
  • Sports
  • Entertainment
  • More
    • Education
    • Celebrities
    • Culture and Arts
    • Environment
    • Health and Wellness
    • Lifestyle
Follow US
© 2024 americanfocus.online – All Rights Reserved.
American Focus > Blog > Economy > Here’s What to Expect From Johnson & Johnson’s Next Earnings Report
Economy

Here’s What to Expect From Johnson & Johnson’s Next Earnings Report

Last updated: June 28, 2025 4:00 am
Share
Here’s What to Expect From Johnson & Johnson’s Next Earnings Report
SHARE

Johnson & Johnson (JNJ) is a leading healthcare company headquartered in New Brunswick, New Jersey. The company is known for its research and development, manufacturing, and sale of various healthcare products worldwide. With a market capitalization of $366.4 billion, Johnson & Johnson operates through its Innovative Medicine and MedTech segments.

The company is gearing up to announce its second-quarter results on Wednesday, July 16. Analysts are projecting a non-GAAP earnings of $2.65 per share, a 6% decrease from the previous year. Despite the anticipated decline, Johnson & Johnson has consistently exceeded analysts’ expectations in recent quarters. For the full fiscal year 2025, earnings are expected to reach $10.60 per share, representing a 6.2% increase from the previous year. In fiscal 2026, earnings are projected to rise by 3.6% year-over-year to $10.98 per share.

Over the past 52 weeks, JNJ stock has shown a 3.5% growth, outperforming the Health Care Select Sector SPDR Fund’s 8.1% decline but falling short of the S&P 500 Index’s 12.1% increase during the same period. Despite delivering better-than-expected financial results in the first quarter, Johnson & Johnson’s stock experienced a slight dip initially. However, the company’s solid growth in US sales led to a 2.4% year-over-year increase in overall revenue to $21.9 billion. Additionally, adjusted earnings per share rose by 2.2% to $2.77, exceeding consensus estimates.

Analysts have a cautiously optimistic outlook on JNJ, with a “Moderate Buy” rating overall. Of the 23 analysts covering the stock, nine rate it as a “Strong Buy,” two as a “Moderate Buy,” and 12 as a “Hold.” The mean price target of $169.14 suggests an 11.3% upside potential from the current price levels.

See also  Banks aren't in the clear just yet

In conclusion, Johnson & Johnson continues to demonstrate resilience and growth in the healthcare industry. Investors are eagerly awaiting the company’s upcoming earnings report to gain further insights into its financial performance and future outlook. This article was originally published on Barchart.com and is intended for informational purposes only.

TAGGED:EarningsExpectHeresJohnsonJohnsonsreport
Share This Article
Twitter Email Copy Link Print
Previous Article Creating Bird Flu Vaccines for Humans at a Biosecure Laboratory Creating Bird Flu Vaccines for Humans at a Biosecure Laboratory
Next Article Summer 2025 Hot Shots … June Gloom?! More Like June Bloom! Summer 2025 Hot Shots … June Gloom?! More Like June Bloom!
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Popular Posts

John Sarcone claims knife-wielding illegal migrant who threatened him ‘was going to kill somebody’

US attorney for New York, John Sarcone, had a terrifying encounter with a knife-wielding illegal…

June 21, 2025

‘Point of pride’: Dems revel in California House wins despite nationwide losses

Democrats in California and New York celebrated victories in key House races, providing a glimmer…

December 5, 2024

The Cinematic Dreaming of Ryuichi Sakamoto

The Museum of Contemporary Art Tokyo is currently hosting a groundbreaking exhibition titled "Seeing Sound,…

March 21, 2025

‘Evil Stepmom’ Kimberly Sullivan, 56, Arrested for ‘Holding Stepson’

A shocking case has emerged from Connecticut, where a woman named Kimberly Sullivan has been…

March 13, 2025

Audi’s F1 future could be in doubt as parent company Volkswagen set to introduce a cost-saving plan, claims F1 pundit 

Audi's Entry to F1 in Doubt Due to Financial Strain Renowned F1 pundit Joe Saward…

September 15, 2024

You Might Also Like

Edgewise Therapeutics price target lowered to  from  at Wedbush
Economy

Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush

June 28, 2025
Israel’s Benjamin Netanyahu weighs his next move after Iran war
Economy

Israel’s Benjamin Netanyahu weighs his next move after Iran war

June 28, 2025
Meta seeks bn from private credit giants to fund AI data centres
Economy

Meta seeks $29bn from private credit giants to fund AI data centres

June 28, 2025
What to Expect From Bank of America’s Report
Economy

What to Expect From Bank of America’s Report

June 28, 2025
logo logo
Facebook Twitter Youtube

About US


Explore global affairs, political insights, and linguistic origins. Stay informed with our comprehensive coverage of world news, politics, and Lifestyle.

Top Categories
  • Crime
  • Environment
  • Sports
  • Tech and Science
Usefull Links
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • DMCA

© 2024 americanfocus.online –  All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?